The Journal of Rheumatology 2022;xx:xxxx
doi:10.3899/jrheum.221074
First Release December 15 2022

The Journal of Rheumatology

Letter

COVID-19 and IgA Vasculitis

To the Editor:

We would like to discuss the article recently published in *The Journal of Rheumatology*, entitled "Immunoglobulin A Vasculitis Following COVID-19: A French Multicenter Case Series" by Ramdani et al.[1] This case series of individuals who developed IgA vasculitis (IgAV) after contracting SARS-CoV-2 describes the formation of IgAV shortly after coronavirus disease 2019 (COVID-19) infection; however, it was unable to completely rule out a coincidental connection between these 2 events.[1] In most patients, the SARS-CoV-2 infection was paucisymptomatic. The authors advised reverse transcription-PCR tests to identify COVID-19 in patients who had no obvious IgAV triggers.[1]

Given that comorbidity can be challenging to manage, it is imperative to investigate any potential COVID-19 vaccine issues.[2] Typically, this is not a good alternative if a clinical problem arises following the vaccination. Before receiving a vaccination, it is crucial to rule out any underlying diseases or comorbidities that may potentially lead to a clinical problem. Patients with SARS-CoV-2 may not be identified because they show no symptoms. If there is a hidden comorbidity, it might be easily mistaken to be a negative effect of the immunization.[3] Further, recent research[4] has associated underlying genetic variance with immune responses to the COVID-19 vaccine among recipients. Future studies should consider the many genetic background elements.

Rujittika Munmunpuntipantip[1], PhD
Viroj Wiwanitkit[2], MD
[1]Private Academic Consultant, Bangkok, Thailand;
[2]University Centre for Research & Development Department of Pharmaceutical Sciences, Chandigarh University Gharuan, Mohali, Punjab, India.

The authors declare no conflicts of interest relevant to this article.

Address correspondence to Dr. R. Mungmunpuntipantip, Private Academic Consultant, 111 Bangkok 122, Bangkok 1033000, Thailand. Email: rujittika@gmail.com.

REFERENCES

1. Ramdani Y, Galempoix JM, Augusto JF, et al. Immunoglobulin A vasculitis following COVID-19: a French multicenter case series. J Rheumatol 2022;49:1390-4.
2. Joob B, Wiwanitkit V. Letter to the editor: coronavirus disease 2019 (COVID-19), infectivity, and the incubation period. J Prev Med Public Health 2020 Mar;53:70.
3. Kebayoon A, Wiwanitkit V. Dengue after COVID-19 vaccination: possible and might be missed. Clin Appl Thromb Hemost 2021;27:10760296211047229.
4. Čiučiulkaitė I, Möhlendick B, Thümmler L, et al. GNB3 c.825c>T polymorphism influences T-cell but not antibody response following vaccination with the mRNA-1273 vaccine. Front Genet 2022;13:932043.